Hip structural analysis of teriparatide vs placebo for postmenopausal osteoporotic women .
The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk
Bone. 2014 Jul;64:75-81209 postmenopausal osteoporotic women who were randomized in the TOWER trial in 2012 were analyzed to evaluate bone structural and strength changes at the hip after treatment with Teriparatide injection or placebo over 72 weeks. Patients were evaluated using hip structural analysis (HSA) based on dual-energy X-ray absorptiometry. The evidence presented in this trial demonstrated that Teriparatide treatment produced significantly higher bone mineral density (BMD), average cortical thickness, bone cross-sectional area, section modulus, and lower buckling ratio at both the narrowest point of the neck (NN) and the intertrochanteric region (IT) compared to the placebo treatment.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
